Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
-- Statistically significant differences demonstrated between DAYBUE™ and placebo on efficacy endpoints relevant to Rett syndrome suggest treatment potentially capable of modifying core... | June 8, 2023
Source: marketscreener.com